Esperion Therapeutics Aktie
WKN DE: A1W1SJ / ISIN: US29664W1053
02.06.2025 15:18:33
|
Esperion Reveals Patent Settlement Agreement With Hetero USA For Cholestrol Drug Nexletol
(RTTNews) - Esperion Therapeutics, Inc. (ESPR), a commercial stage biopharma company, on Monday announced a patent litigation settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Ltd., Hetero Labs Ltd. Unit-V, and Honour Lab Ltd. As per the agreement, Hetero USA has agreed not to market a generic version of Nexletol in the US, prior to April 19, 2040.
Hetero USA had submitted Abbreviated New Drug Application or ANDA seeking approval to market a generic version of Nexletol prior to the expiration of the applicable patents. Nexletol is prescribed to lower cholesterol in blood.
The company said Nexletol patent litigation against the remaining defendants for such as Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo Pharma Ltd., Dr. Reddys Laboratories Inc., MSN Pharmaceuticals Inc., Renata Ltd; and Sandoz Inc. are ongoing.
Earlier in May, Esperion has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Ltd. to resolve a patent litigation on Nexletol.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Esperion Therapeutics Incmehr Nachrichten
04.08.25 |
Ausblick: Esperion Therapeutics präsentiert Quartalsergebnisse (finanzen.net) | |
05.05.25 |
Ausblick: Esperion Therapeutics mit Zahlen zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Esperion Therapeutics Incmehr Analysen
Aktien in diesem Artikel
Esperion Therapeutics Inc | 2,64 | 28,41% |
|